Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine

Stefano, Isabel Cristina Aparecida; Sato, Helena Keiko; Pannuti, Cláudio Sérgio; Omoto, T. M.; Mann, G. F.; Freire, Marcos S.; Yamamura, Anna Maya Yoshida; Vasconcelos, Pedro F.C.; Oselka, Gabriel Wolf; Weckx, Lily Yin; Salgado, María; Noale, Lucelene F.O; Souza, Vanda Auf

doi:10.1016/s0264-410x(98)00320-x

Cited by 70 publications

(47 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…43,44 However, more recent studies have not supported these observations. 7,26,30,[45][46][47][48] Children may not develop an immunologic response as effectively as adults or may lose immunity more rapidly. However, these studies have methodologic limitations, including use of an intraperitoneal protection test for young mice, which was later found to be less sensitive than newer techniques or the use of old vaccination records to recruit persons.…”

Section: Americanmentioning

confidence: 99%

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Gotuzzo¹,

Yactayo²,

Córdova³

2013

The American Society of Tropical Medicine and Hygiene

207

172

View full text Add to dashboard Cite

Abstract. Current regulations stipulate a yellow fever (YF) booster every 10 years. We conducted a systematic review of the protective efficacy and duration of immunity of YF vaccine in residents of disease-endemic areas and in travelers to assess the need for a booster in these two settings and in selected populations (human immunodeficiency virus-infected persons, infants, children, pregnant women, and severely malnourished persons). Thirty-six studies and 22 reports were included. We identified 12 studies of immunogenicity, 8 of duration of immunity, 8 of vaccine response in infants and children, 7 of human-immunodeficiency virus-infected persons, 2 of pregnant women, and 1 of severely malnourished children. Based on currently available data, a single dose of YF vaccine is highly immunogenic and confers sustained life-long protective immunity against YF. Therefore, a booster dose of YF vaccine is not needed. Special considerations for selected populations are detailed.

show abstract

Section: Americanmentioning

confidence: 99%

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Gotuzzo¹,

Yactayo²,

Córdova³

2013

The American Society of Tropical Medicine and Hygiene

207

172

View full text Add to dashboard Cite

show abstract

“…The YF 17DD vaccine, produced in Bio-ManguinhosFiocruz, Brazil, is known to be a safe and efficient vaccine, leading to suitable results with regards to nAb production (Stefano et al 1999, WHO 2001b, Marchevsky et al 2003. However, the cellular immune response profile of the YF 17DD vaccine has not been known as yet, although some rare adverse events after vaccination have been suggested as a failure in the cellular immune response of these patients , Mariannaeu et al 2001, Vasconcelos et al 2001.…”

Section: Discussionmentioning

confidence: 99%

“…were carried out in 96-well plates as described elsewhere (Stefano et al 1999). In brief, dilutions of the sera ranging from 1:4 to 1:512 were mixed with 1:1200 of the 17DD virus preparation (7.8 log 10 PFU/ml).…”

Section: Plaque Reduction Neutralization Test (Prnt) -Prntmentioning

confidence: 99%

Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus

Santos¹,

Bertho

Dias³

et al. 2005

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

In this study the kinetics of humoral and cellular immune responses in first-time vaccinees and re-vaccinees with the yellow fever 17DD vaccine virus was analyzed. Flow cytometric analyses were used to determine percentual values of T and B cells in parallel to the yellow fever neutralizing antibody production. All lymphocyte subsets analyzed were augmented around the 30th post vaccination day, both for first-time vaccinees and re-vaccinees. CD3 + T cells increased from 30.8% (SE ± 4%) to 61.15% (SE ± 4.2%), CD4 + T cells from 22.4% (SE ± 3.6%) to 39.17% (SE ± 2%) with 43% of these cells corresponding to CD4 + CD45RO + T cells, CD8 + T cells from 15.2% (SE ± 2.9%) to 27% (SE ± 3%) with 70% corresponding to CD8 + CD45RO + T cells in first-time vaccinees. In revaccinees, the CD3 + T cells increased from 50.7% (SE ± 3%) to 80% (SE ± 2.3%), CD4 + T cells from 24.9% (SE ± 1.4%) to 40% (SE ± 3%) presenting a percentage of 95% CD4 + CD45RO + T cells, CD8 + T cells from 19.7% (SE ± 1.8%) to 25% (SE ± 2%Key words: yellow fever -vaccine -flow cytometry -neutralizing antibodies -lymphocyte subsets Yellow fever (YF) is a viral illness transmitted by infected mosquitoes (Aedes and Haemagogus genus) with yellow fever virus (YFV), which belongs to the Flavivirus genus, Flaviviridae family (Monath & Heinz 1996). It remains a serious health problem in endemic areas of tropical and subtropical Africa and South America (Vasconcelos 2003). Since the 19th century, studies about YF immunization have been accomplished (WHO 2001a). The YF 17D vaccine virus strain is one of the most effective and safe vaccines available. Immunization with the 17D vaccine strain induces a long-term neutralizing antibody response and provides excellent protection against infection with the virulent YFV (Wisseman & Sweet 1962). In 1937, the production of the YF 17DD vaccine virus substrain was started in Brazil, and has been in continuous use for 60 years (Post et al. 2001). The YFV 17DD vaccine is highly immunogenic and induces neutralizing antibody persistent at least 10 years and in some individuals up to 30 years or more (WHO 2001b).Although the YF 17D virus strain and the 17DD substrain are the most successful vaccines developed to date, recently, rare cases of postvaccinal neurological disorders have been recorded (Chan et al. 2001, Martin et al. 2001, Vasconcelos et al. 2001 .Despite the large literature on the humoral immune response to the YF vaccine virus, few works of the evaluation of cellular immune response, in particular T cell responses have been published (Reinhardt et al. 1998, Co et al. 2002, van der Most et al. 2002. The capacity of vaccines to activate the cellular immune system and induce T cell memory is an important mechanism of protection against wild-type viral infection. T cells often recognize more conserved epitopes that do not change due to antibody mediated selection pressure (Whitton & Oldstone 1996, Reinahrdt et al. 1998. Co and collaborators (2002) studying the T cell responses to YFV 17D in four volunteers could observ...

show abstract

“…At the three time points in the followup period blood was collected for haematological and biochemical determinations (red blood cells, hematocrit, haemoglobin, leukocytes, platelets, urea, creatinin, glycemia, TGO, TGP, amylase, alkaline phosphatase, time of prothrombin, total and fractionate bilirubin), viremia 14 , and anti-yellow fever virus antibodies 12 .…”

Section: Methodsmentioning

confidence: 99%

Low frequency of side effects following an incidental 25 times concentrated dose of yellow fever vaccine

Rabello¹,

Orsini²,

Disch³

et al. 2002

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

In August/1999, a group of 14 adults from the staff of a private hospital in Contagem -- Minas Gerais State, Brazil, received unintentionally a 25 times concentrated dose of the 17-DD yellow fever vaccine (Bio-Manguinhos), due to a mistake at the reconstitution step. All patients were clinically and laboratorially evaluated at days 5, 13 and 35 post vaccination. Frequency of side effects and clinical observations of this group of individuals were not different from the observed in recipients immunized with normal doses of the vaccine. At the second and third evaluation none of the subjects reported symptoms. None of the patients presented abnormalities at the physical examination at none of the time points and in all cases the blood examination was normal, except for a reduced number of platelets that was detected in one subject at the first and second evaluation and reverted to normal at third evaluation. At the first evaluation point, 8 subjects were serum negative and 6 serum positive for yellow fever at the plaque reduction neutralization test. In 5 subjects the observed titre was 10 times higher as the baseline of 2.36 Log10 mUI/ml. The samples collected at second and third evaluation (13th and 35th days) demonstrated that all subjects responded to the vaccination with the exception of one that did not present a positive result in any of the samples collected. This evaluation confirms the safety of the 17-DD yellow fever vaccine.

show abstract

Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine

Cited by 70 publications

References 13 publications

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus

Low frequency of side effects following an incidental 25 times concentrated dose of yellow fever vaccine

Contact Info

Product

Resources

About